Mogamulizumab

Product NameMogamulizumab
CAS1159266-37-1
MF
MW0
EINECS
MOL FileMol File

Chemical Properties

form	Liquid
color	Colorless to light yellow

Usage And Synthesis

Uses

Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL)[1][2][3].

in vivo

Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) together with PBMC transplantation inhibits the growth of EBV-positive NK-cell lymphomas in a murine xenograft model^[2].
Mogamulizumab (0.1 mg/kg, i.v., every other day) together with canine PBMCs (every fourth day)), inhibits tumor growth in canine bladder cancer-engrafted mouse model^[4].
Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4⁺CCR4⁺ T cells, with no adverse effect in dogs^[4].

Animal Model:	Murine xenograft model, constructed by using the immunodeficient NOG mouse and the EBV-positive NK-cell lymphoma cell line (SNK6)^[2]
Dosage:	1 mg/kg
Administration:	Intraperitoneal injection (i.p.), together with PBMC transplantation; twice per week for 4 weeks.
Result:	Suppressed Tumor growth with vacuolar degeneration.

IC 50

CCR4

References

[1] Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016 Jun;7(3):171-4. DOI:10.1177/2040620716636541
[2] Kanazawa T, et al. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases. Clin Cancer Res. 2014 Oct 1;20(19):5075-84. DOI:10.1158/1078-0432.CCR-14-0580
[3] Yamauchi J, et al. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy. J Infect Dis. 2015 Jan 15;211(2):238-48. DOI:10.1093/infdis/jiu438
[4] Maeda S, et al. CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer. Cancer Immunol Res. 2019 Jul;7(7):1175-1187. DOI:10.1158/2326-6066.CIR-18-0751

Mogamulizumab Supplier

Mogamulizumab manufacturers

Send Inquriy